Comparisons of follow-up of GH-treated and untreated cancer patients in the United States and United Kingdom (5, 6) have given some evidence of raised risk of meningioma associated with GH, although a later analysis from the US cohort (7) did not find raised risk. This evidence concerns the gene GH1 and cancer.